Zai Lab Limited (9688.HK)
9688.HK Stock Price Chart
Explore Zai Lab Limited interactive price chart. Choose custom timeframes to analyze 9688.HK price movements and trends.
9688.HK Company Profile
Discover essential business fundamentals and corporate details for Zai Lab Limited (9688.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Sept 2020
Employees
1.87K
Website
https://www.zailaboratory.comCEO
Ying Du
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
9688.HK Financial Timeline
Browse a chronological timeline of Zai Lab Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at -$0.29 falling short of the estimated -$0.04 by -631.92%, while revenue for the quarter reached $863.26M , beating expectations by +475.36%.
Earnings released on 7 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $827.61M , beating expectations by +548.77%.
Earnings released on 25 Feb 2025
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $847.23M , beating expectations by +669.18%.
Earnings released on 13 Nov 2024
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%, while revenue for the quarter reached $794.21M , beating expectations by +629.59%.
Earnings released on 7 Aug 2024
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $784.94M , beating expectations by +6.44%.
Earnings released on 9 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $681.92M , beating expectations by +12.13%.
Earnings released on 28 Feb 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $514.06M , missing expectations by -10.53%.
Earnings released on 8 Nov 2023
EPS came in at -$0.07 surpassing the estimated -$0.13 by +46.15%, while revenue for the quarter reached $541.86M , missing expectations by -2.74%.
Earnings released on 8 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.44 by +70.45%, while revenue for the quarter reached $539.58M , beating expectations by +1.45%.
Earnings released on 10 May 2023
EPS came in at -$0.51 surpassing the estimated -$1.05 by +51.43%, while revenue for the quarter reached $492.93M , missing expectations by -6.25%.
Earnings released on 2 Mar 2023
EPS came in at -$0.65 surpassing the estimated -$1.01 by +35.64%, while revenue for the quarter reached $488.45M , missing expectations by -0.66%.
Earnings released on 10 Nov 2022
EPS came in at -$1.68 falling short of the estimated -$0.87 by -93.10%, while revenue for the quarter reached $451.66M , beating expectations by +7.06%.
Earnings released on 10 Aug 2022
EPS came in at -$1.44 falling short of the estimated -$0.90 by -60.00%, while revenue for the quarter reached $378.00M , beating expectations by +2.18%.
Earnings released on 11 May 2022
EPS came in at -$0.86 surpassing the estimated -$0.98 by +12.54%, while revenue for the quarter reached $365.89M , beating expectations by +4.71%.
Stock split effective on 14 Apr 2022
Shares were split 10 : 1 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 30 Mar 2022
Shares were split 10 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Mar 2022
EPS came in at -$0.22 falling short of the estimated -$0.18 by -22.22%, while revenue for the quarter reached $344.41M , missing expectations by -7.77%.
Earnings released on 10 Nov 2021
EPS came in at -$0.10 surpassing the estimated -$0.17 by +41.18%, while revenue for the quarter reached $335.56M .
Earnings released on 10 Aug 2021
EPS came in at -$0.18 surpassing the estimated -$0.25 by +28.00%, while revenue for the quarter reached $286.79M .
Earnings released on 11 May 2021
EPS came in at -$0.26 , while revenue for the quarter reached $156.30M .
Earnings released on 2 Mar 2021
EPS came in at -$6.55 , while revenue for the quarter reached $113.55M .
Earnings released on 31 Dec 2020
EPS came in at -$6.78 , while revenue for the quarter reached $117.02M .
9688.HK Stock Performance
Access detailed 9688.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.